Multiple Sclerosis Trial, Recruiting NCT06920524 Sponsor: University Hospital, Clermont-Ferrand Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06920524
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults (male or female) who have muscle stiffness or spasms caused by a neurological condition (such as multiple sclerosis, stroke, or brain injury) and who are already receiving or are suitable for botulinum toxin (such as Botox) injections as part of their treatment.
  • People who experience known pain and/or anxiety related to their condition.
  • People who are able to understand the study and give their formal agreement to take part in research.
  • People who are enrolled in the French Social Security system.

Who may not be able to join:

  • People for whom music-based activities are not suitable, including those with severe hearing loss, unstabilised psychotic disorders, or a history of auditory trauma.
  • People with significant memory or thinking difficulties that would make participation not possible.
  • People with any other health condition that the investigating doctor considers to be incompatible with taking part in the study.
  • People who require a specific type of sedation gas (MEOPA) during their botulinum toxin injection sessions.
  • People taking certain medications — including beta-blockers, anti-arrhythmics, anti-anxiety medications, benzodiazepines, blood pressure medications, or calcium antagonists — or who have medical conditions that could affect heart rate measurements during the study (confirm with trial site).
  • Women who are pregnant or breastfeeding.
  • People who do not wish to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marina BADIN, University Hospital, Clermont-Ferrand

Phone: +33473754963

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 April 2025
Est. completion
30 October 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Stress; Stress

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov